PT-141 is another name for bremelanotide, the active ingredient in Vyleesi. The FDA approved that prescription product in 2019 for a specific form of low sexual desire in premenopausal women. That is a narrower claim than saying a peptide boosts libido for everyone. [1]
A research vial, an online nasal spray and the prescription medicine are different products. Sharing an ingredient name doesn’t make their evidence or instructions interchangeable.
Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see PT-141 (10 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.
What is PT-141 actually used for?
Vyleesi’s approved use is acquired, generalized hypoactive sexual desire disorder, or HSDD, in women who have not reached menopause. The low desire causes substantial distress or relationship difficulty and is not explained by another medical or psychiatric condition, relationship problems, or medication or substance effects. [1]
Acquired means the problem developed after a period without it. Generalized means it is not limited to a particular situation, stimulation or partner. The diagnosis is more specific than occasionally not feeling interested in sex. [2]
MedlinePlus makes the boundary clear: this medicine is not intended for men, postmenopausal HSDD, or improving sexual performance. A clinician needs to assess the reason for low desire before considering treatment. [3]
How does PT-141 work?
Bremelanotide activates melanocortin receptors. Early research explored how these nervous-system pathways affect sexual responses, including erections. That helps explain why a synthetic peptide became a sexual-health research subject. It does not mean it can reliably create desire on demand. [4]
The prescribing information still says the precise mechanism behind its HSDD benefit is unknown. It is not testosterone replacement, and describing it as a universal “libido switch” overstates what is known. [2]
What benefits did the clinical trials find?
The two RECONNECT trials randomized 1,267 premenopausal women with HSDD to bremelanotide or placebo. Treatment lasted 24 weeks. On average, the bremelanotide groups improved more on questionnaires measuring sexual desire and distress related to low desire. [5]
Satisfying sexual events did not increase significantly compared with placebo. The trials supported particular questionnaire outcomes, not a guarantee of better sexual performance or every possible sexual-health benefit.
Most participants were White and almost all were enrolled in the United States. The studies were funded by the drug’s developers. These details do not erase the findings, but they matter when judging how broadly the results apply. They also do not answer whether a differently made product would produce the same results.
Quick reader check: does an improved desire score guarantee more satisfying sex?
No. Desire, distress and satisfying sexual events were separate outcomes. Improvement in one measure does not prove improvement in the others. A useful treatment discussion starts with the specific problem the person wants help with.
PT-141 for men: what the early research shows
There is real male research, but it is different from the evidence behind Vyleesi’s approval. In a 2004 study, investigators assessed injected PT-141 in healthy men and men reporting an inadequate response to sildenafil. They measured erectile responses with RigiScan, a monitoring device, and reported a response in the studied conditions. [6]
A separate 2005 crossover study involved 19 men and tested intranasal PT-141 alongside sildenafil. The combination produced a greater measured erectile response than sildenafil alone. This was a small, controlled experiment, not a demonstration that arbitrary nasal sprays work or that combining these drugs without supervision is safe. [7]
Neither study establishes that PT-141 is generally better than Viagra, nor that it is the right treatment for a particular man’s erectile dysfunction. Low desire and difficulty getting an erection are different problems. A comparison should specify the diagnosis, product, outcome and safety context instead of declaring a winner.
PT-141 side effects: what the numbers show
Selected trial rates from Vyleesi’s prescribing information are shown below. [2]
| Reaction | Vyleesi 627 participants |
Placebo 620 participants |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Injection-site reactions | 13.2% | 8.4% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | 0.2% |
These percentages are trial observations, not a complete list of possible reactions or a personal risk calculation.
Who needs particular caution?
Bremelanotide can raise blood pressure and lower heart rate temporarily. People with uncontrolled high blood pressure or known heart disease should not use it. Tell the prescriber about kidney or liver disease, pregnancy plans and breastfeeding. [3]
Darkening of areas of skin can also occur and may persist after stopping. A higher risk was reported in people with darker skin and with frequent use. Discuss new pigmentation or troublesome side effects with the prescriber.
Medication review matters too. The label warns that bremelanotide can slow oral-drug absorption and reduce exposure to oral naltrexone used for alcohol or opioid addiction; that combination should be avoided. [2]
Prescription product, compounded medicine or research vial?
Vyleesi is supplied as a ready-to-use, single-dose autoinjector. It is not a powder that the patient needs to reconstitute. [2]
A compounded medicine is another category. The FDA explains that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness and quality before marketing. Compounding can meet particular medical needs, but it does not confer the approval held by the branded product. [8]
An online research vial should not be assumed to be either of those products. A supplier’s purity percentage does not establish equivalence to the formulation used in a clinical trial. Likewise, an old nasal-spray experiment does not validate a currently advertised spray.
Timing and dosage: why the formulation matters
For prescribed bremelanotide, MedlinePlus describes use at least 45 minutes before sexual activity, with no more than one dose in 24 hours or eight doses in a month. Patients should contact their clinician if symptoms have not improved after eight weeks. These are boundaries for the prescription medicine, not instructions for preparing research peptides. [3]
Forty-five minutes is not a guarantee of a noticeable response at that moment. Follow the prescriber’s instructions rather than adding doses because an expected effect has not occurred.
The site’s PT-141 10 mg reference chart covers a different vial format. Its concentration calculations cannot establish that a research product is equivalent to Vyleesi or suitable for personal treatment.
What to ask a healthcare professional
- Is the main concern low desire, distress, erection difficulty, pain or something else?
- Could medicines, health conditions or relationship factors explain the change?
- Does the evidence apply to the exact product and diagnosis being discussed?
- What would count as a worthwhile benefit, and when should treatment be reassessed?
Bottom line: PT-141 has genuine clinical research behind it, but that evidence is specific. It does not turn every vial or every libido claim into a proven treatment. Use the research to inform a conversation with a qualified clinician, not to bypass one.
References
- U.S. Food and Drug Administration. Vyleesi approval letter, June 21, 2019. NDA 210557.
- DailyMed. Vyleesi prescribing information. Cosette Pharmaceuticals; current record checked October 5, 2026.
- MedlinePlus. Bremelanotide injection: patient medicine information.
- Molinoff et al. (2003). PT-141 and melanocortin signaling in sexual dysfunction research. Annals of the New York Academy of Sciences.
- Kingsberg et al. (2019). Two randomized phase 3 trials of bremelanotide for HSDD. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003500.
- Rosen et al. (2004). Subcutaneous PT-141 in healthy men and men with erectile dysfunction. International Journal of Impotence Research. doi:10.1038/sj.ijir.3901200.
- Diamond et al. (2005). Intranasal PT-141 with sildenafil in a 19-man crossover study. Urology. doi:10.1016/j.urology.2004.10.060.
- U.S. Food and Drug Administration. Understanding the risks of compounded drugs.
Related dosage protocols and research
Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable.
Matching dosage protocols
Related protocols and comparisons
Further research context